Back to Journals » Psoriasis: Targets and Therapy

ESCI

Impact Factor

Psoriasis: Targets and Therapy

ISSN: 2230-326X

Journal Articles:

- 214 records -

Original Research

Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study

Mrowietz U, Sommer R, Reguiai Z, Gerdes S, Daudén E, Weger W, Maul JT, Naldi L, Ghislain PD, Laws PM, De Jong EMGJ, Mburu S, Koscielny V, Massana E, Sapena V, Domenech A, Kasujee I, Augustin M

Psoriasis: Targets and Therapy 2026, 16:590189

Published Date: 12 May 2026

Original Research

Genetic Evidence Linking Immune Cell Subsets to Psoriatic Arthritis Susceptibility: A Mendelian Randomization Study

Wang H, Ma M, Wang C, Zhen Y, Li S

Psoriasis: Targets and Therapy 2026, 16:589733

Published Date: 16 April 2026

Original Research

Core Differentially Expressed Genes in Psoriasis Lesions: An Integrated Analysis of Four GEO Datasets

Ennouri M, Görmez Z, Bahloul E, Becha MK, Elleuch NB, Inal-Gültekin G

Psoriasis: Targets and Therapy 2026, 16:580680

Published Date: 3 April 2026

Review

Application of Trichoscopy and Novel Non-Invasive Imaging Techniques in the Diagnosis and Management of Patients with Scalp Psoriasis

Kuchnicka A, Fałkowska U, Konopelski P, Anderson A, Rakowska A, Kurzeja M, Olszewska M, Rudnicka L

Psoriasis: Targets and Therapy 2026, 16:549372

Published Date: 30 March 2026

Original Research

Indole-3-Lactic Acid Attenuates IMQ-Induced Psoriasiform Dermatitis in Mice via AhR-Dependent Suppression of IL-17A

Meng Z, Ren J, Lai Y, Lu S, Wu H, Jiang Y, Zhang Z, Tan G, Shi Z

Psoriasis: Targets and Therapy 2026, 16:585731

Published Date: 27 March 2026

Expert Opinion

The Psoriatic Disease Assessment Index (PSODAI) Score to Evaluate Systemic Involvement of Psoriasis

Liang Y, Deng B, Ntawuyamara E, Bachelez H, Wang F, Zhang H, Zhang Z, Li Z, Dang L, Wang Y, Zou X, Wang L, Duan D, Chen H, Zheng W, Huang H, Zhang M, Cai Q, Chen Y, Zhang Y, Lu Z, Ren Y, Huang J

Psoriasis: Targets and Therapy 2026, 16:548700

Published Date: 16 February 2026

Original Research

Persistence and Long-Term Disease Control of Interleukin-17 Inhibitors and Interleukin-23 Inhibitors in Patients with Psoriasis: A Nationwide Cohort Study in Japan

Xu Y, Li T, Chang CL, Zhang Y, Masuda J, Wu GHM, Wahking B, Imafuku S, Qiu H

Psoriasis: Targets and Therapy 2026, 16:565823

Published Date: 11 February 2026

Original Research

Prevalence of Genital Psoriasis and Its Impact on Patients’ Sexual Life in Routine Care: Epidemiologic Survey in Germany

Janke TM, Sorbe C, Sommer R, Bickert T, Mrowietz U, Gomis-Kleindienst S, Schild M, Lohmann K, Augustin M

Psoriasis: Targets and Therapy 2026, 16:516803

Published Date: 21 January 2026

Original Research

Bidirectional Associations Between Substance Abuse and Psoriasis: A Prospective Cohort Study

Che X, Zhou J, Wang A, Guo J, Zhang C, Xiao Y

Psoriasis: Targets and Therapy 2026, 16:557781

Published Date: 7 January 2026

Case Series

Successful Treatment of Two Rare Pediatric Keratinization Disorders with Secukinumab: Epidermolytic Ichthyosis and PRP–GPP Overlap

Xu Q, Zhang J

Psoriasis: Targets and Therapy 2026, 16:553794

Published Date: 6 January 2026

Original Research

Real-World Experience of Guselkumab in the Elderly Population

Fratton Z, Bighetti S, Bettolini L, Maione V, Rossi M, Venturini M, Mazzoletti V, Zelin E, Stinco G, Errichetti E

Psoriasis: Targets and Therapy 2025, 15:581-601

Published Date: 26 December 2025

Original Research

Global Trends and Future Predictions of Psoriasis Burden: Insights from the GBD 2021 Study

Gu X, Wang X, Bin Y, Xue R, Zhu G

Psoriasis: Targets and Therapy 2025, 15:569-580

Published Date: 24 December 2025

Original Research

Antibodies Targeting Gasdermin E as a Potential Therapeutic Option for Psoriasis – A Pilot Study on a Mouse Model

Nowowiejska-Purpurowicz J, Hermanowicz JM, Pawlak D, Flisiak I, Lipinski T

Psoriasis: Targets and Therapy 2025, 15:561-567

Published Date: 18 December 2025

Original Research

PEGylated Peptide for Targeted Inhibition of Human Antigen R as a Novel Therapeutic Strategy for Psoriasis: A Proof-of-Concept Study

Chen YF, Jiang YS, Chen YC, Chang CH, Jan JS

Psoriasis: Targets and Therapy 2025, 15:545-559

Published Date: 29 November 2025

Original Research

Neurofunctional Reversibility in Psoriasis Vulgaris After IL-17A Inhibition: A Resting-State fMRI and Neurocognitive Analysis

Liu J, Fan H, Sun R, Pang Y, Li X, Ma Q, Xu C, Zhang D, Ma W

Psoriasis: Targets and Therapy 2025, 15:535-543

Published Date: 31 October 2025

Original Research

Predictors of Successful Secukinumab Dose Tapering in Moderate-to-Severe Psoriasis: A Retrospective Study

Chen J, Xiao Z, Zeng X, Xiang N, Luo R, Chen R, Lin B, Ke H, Gong T, Ji C

Psoriasis: Targets and Therapy 2025, 15:527-534

Published Date: 17 October 2025

Original Research

Evaluating the Role of Disease Duration in Systemic Therapy Response Among Patients with Moderate-to-Severe Psoriasis

Dai M, Jiang Y, Xi Y, Xu L, Huang D, Wang Y, Hu Y, Yu Q, Shi Y

Psoriasis: Targets and Therapy 2025, 15:513-525

Published Date: 13 October 2025

Original Research

Integrated Single-Cell RNA Sequencing and Proteome-Wide Mendelian Randomization Identifies Therapeutic Targets for Psoriasis and Associated Complications

Zheng P, Cao Y, Wang A, Yi K

Psoriasis: Targets and Therapy 2025, 15:501-511

Published Date: 10 October 2025

Original Research

Codon-Usage Bias and Genomic Architecture of 79 Psoriasis-Susceptibility Genes: Implications for Expression Efficiency and Therapeutic Targeting

Jiang S, Chen L, Li J, Gao F, Yan X, Zhao Y

Psoriasis: Targets and Therapy 2025, 15:479-499

Published Date: 25 September 2025

Case report

Vunakizumab for Treatment of Acrodermatitis Continua of Hallopeau: A Case Report and Literature Review

Yao Y, Ma Y, Zhong H, Guo F, Zhu J, Wu Y, Tang S

Psoriasis: Targets and Therapy 2025, 15:471-478

Published Date: 23 September 2025

Original Research

Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study

Mortato E, Talamonti M, Marcelli L, Megna M, Raimondo A, Caldarola G, Bernardini N, Balato A, Campanati A, Esposito M, Bonifati C, Lora V, Potestio L, Lembo S, Loconsole F, De Luca E, Skroza N, Buononato D, Bianchelli T, Fargnoli MC, Tommasino N, Foti C, De Simone C, Bianchi L, Galluzzo M

Psoriasis: Targets and Therapy 2025, 15:455-469

Published Date: 16 September 2025

Review

Epidemiology of Hypertension in Psoriasis: An Analysis of Trends from 2006 to 2023

Zhang M, Chen JL, Fan SW, Sun XY, Zhou YQ, Luo Y, Wang J, Wang CX, Lin NX, Liu L, Li X

Psoriasis: Targets and Therapy 2025, 15:443-453

Published Date: 27 August 2025

Original Research

Machine Learning-Driven Prediction Models for Brodalumab Therapeutic Effect and Response Speed in Plaque Psoriasis

Peng L, Wang L, Chen L, Shen Z

Psoriasis: Targets and Therapy 2025, 15:429-442

Published Date: 21 August 2025

Review

The Skin-Brain Axis in Psoriasis and Depression: Roles of Inflammation, Hormones, Neuroendocrine Pathways, Neuropeptides, and the Microbiome

Tang L, Bi H, Lin K, Chen Y, Xian H, Li Y, Xie H, Zheng G, Wang P, Chen Y, Yang B, Tan Y, Song Q, Wang M, Li G, Chang J, Guan Y, So KF, Lu C

Psoriasis: Targets and Therapy 2025, 15:411-428

Published Date: 18 August 2025

Review

Biosimilars for the Treatment of Moderate to Severe Chronic Plaque Psoriasis

Gisondi P, Bellinato F, Curic T, Girolomoni G

Psoriasis: Targets and Therapy 2025, 15:401-410

Published Date: 18 August 2025

Original Research

Causal Effect of Plasma Fatty Acid Profiles on Psoriasis Risk: Genetic Evidence from a Mendelian Randomization Study

Yao L, Wang X, Lu D, Tian S

Psoriasis: Targets and Therapy 2025, 15:389-399

Published Date: 16 August 2025

Original Research

Beyond Skin Clearance: Personalized Strategies for DLQI Improvement in Psoriasis -Insights From a Shanghai Prospective Cohort

Ma X, Xu Q, Kuai L, Shen F, Duan Z, Gao X, Zhang R, Wang R

Psoriasis: Targets and Therapy 2025, 15:373-387

Published Date: 13 August 2025

Original Research

TYK2 rs34536443 (P1104A) Variant Suppresses ICAM1-Mediated Inflammation: Insights From Mendelian Randomization and Functional Analyses

Dai B, Tang Y, Zhang B, Xu G, Zhang Y, Ze K

Psoriasis: Targets and Therapy 2025, 15:361-372

Published Date: 12 August 2025

Review

Bimekizumab: The First FDA-Approved Dual IL-17A/IL-17F Inhibitor for Plaque Psoriasis – A Comprehensive Literature Review

Al Alshaikh SA, Almarhoon ZM, Momattin H, Aleid M, Almousa ZH, Alqaisum AK, Mobarki FI, Almakki SA, Alturfi H, Almajed KJ

Psoriasis: Targets and Therapy 2025, 15:351-360

Published Date: 5 August 2025

Original Research

Utilization and Costs of Laboratory Monitoring in Biological and Non-Biological Psoriasis Treatment – Large-Scale Claims Data Analysis

Wagner JN, Hagenström K, Müller KS, Stephan B, Augustin M, von Kiedrowski R

Psoriasis: Targets and Therapy 2025, 15:327-338

Published Date: 5 August 2025

Original Research

Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years

Mastorino L, Dapavo P, Burlando M, Gisondi P, Maronese CA, Ruggiero A, Galluzzo M, Pisani MC, Sacchelli L, Caldarola G, Avallone G, Marzano AV, Megna M, Campione E, Loconsole F, Bardazzi F, De Simone C, Quaglino P, Ribero S

Psoriasis: Targets and Therapy 2025, 15:339-350

Published Date: 4 August 2025

Case report

Successful Treatment with Secukinumab in a Psoriasis Patient on Hemodialysis

Xiao Y, Sun J

Psoriasis: Targets and Therapy 2025, 15:321-325

Published Date: 23 July 2025

Review

Update on Erythrodermic Psoriasis: Proposal of a Management Algorithm by an Innovative Severity Evaluation Approach

Xu JM, Wu C, Feng H, Jin HZ

Psoriasis: Targets and Therapy 2025, 15:301-320

Published Date: 19 July 2025

Original Research

Psoriasis Does Not Seem to Impair Glomerular and Tubular Function – The Comprehensive Study on Serum and Urine

Nowowiejska J, Baran A, Hermanowicz JM, Sieklucka B, Koper-Lenkiewicz OM, Kamińska J, Pawlak K, Pawlak D, Flisiak I

Psoriasis: Targets and Therapy 2025, 15:285-299

Published Date: 18 July 2025

Original Research

Epidemiology and Health Care of Generalized Pustular Psoriasis in Germany – Methodology and Outcomes of Claims Data Analysis

Hagenström K, Müller K, Ben-Anaya N, Augustin M

Psoriasis: Targets and Therapy 2025, 15:273-283

Published Date: 15 July 2025

Original Research

Tobacco Smoking Was Positively Associated with Disease Relapse at week 24 and 48 Among Patients with Psoriasis Vulgaris in Shanghai: A Prospective Study

Shen F, Ding Y, Qiang Y, Duan Z, Xu Q, Gao X, Zhang R, Wang R

Psoriasis: Targets and Therapy 2025, 15:261-272

Published Date: 14 July 2025

Original Research

Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study

Mrowietz U, Sommer R, Gerdes S, Reguiai Z, Weger W, Daudén E, Maul JT, Ghislain PD, Laws PM, Naldi L, De Jong E, Mburu S, Koscielny V, Massana E, Domenech A, Gaarn du Jardin K, Kasujee I, Augustin M

Psoriasis: Targets and Therapy 2025, 15:243-259

Published Date: 28 June 2025

Original Research

Effectiveness and Safety of Adalimumab Biosimilars in Pediatric Psoriasis: A Multi-Center International Experience

Bertoli C, Torres T, Romita P, Stingeni L, Hansel K, Mastorino L, Ortoncelli M, Panzone M, Cruz MJ, Bianchi L, Zangrilli A, Musumeci ML, Micali G, Gerbino C, Simonetti O, De Simoni E, Longo C, Mahé E, Di Lernia V

Psoriasis: Targets and Therapy 2025, 15:233-241

Published Date: 28 June 2025

Original Research